Response to pneumococcal polysaccharide vaccination in patients with chronic and allergic aspergillosis

Chris Kosmidis, Georgina Powell, Ray Borrow, Julie Morris, Hana Alachkar, David W Denning

Research output: Contribution to journalArticlepeer-review


INTRODUCTION: Pneumococcal infection causes significant morbidity in patients with underlying lung disease, and vaccination has been associated with reduced disease rates. Response to vaccination has not been studied in chronic lung conditions characterised by ongoing infection or inflammation like chronic pulmonary aspergillosis (CPA).

METHODS: In a prospective observational study, consecutive patients with CPA, allergic aspergillosis and bronchiectasis attending a national referral centre received pneumococcal 23-valent polysaccharide vaccine (PPV-23) and had pre- and post-vaccination antibody concentrations quantified as part of routine clinical care. Serotype-specific pneumococcal IgG antibodies were quantified for 12 serotypes using a multiplex microsphere assay. A protective response was defined as a level of >1.3μg/mL or a ≥ fourfold rise in concentration for ≥70% of serotypes, pre to post-vaccination. C-reactive protein, Immunoglobulins and mannose binding lectin (MBL) levels were measured and correlated to vaccine response.

RESULTS: A total of 318 patients were enrolled. In vaccine-naïve patients (n=127), the lowest pre-vaccination levels were seen with serotypes 1 and 4 and the highest with serotype 19A. A protective response post-vaccination was seen in 50% of patients. The poorest responses were observed with serotypes 1, 3 and 4. Levels of C-reactive protein did not affect efficacy. Profound MBL deficiency was found in 28.8%; there were no significant differences in response to vaccination in patients with or without MBL deficiency. Post-vaccination serotype-specific concentrations waned gradually, however they were still elevated compared to pre-vaccination after 2-5 years.

CONCLUSIONS: Patients with chronic and allergic aspergillosis exhibited a poor response to PPV-23 vaccination compared to healthy adults. An alternative vaccination strategy or delay of vaccination until their underlying condition is better controlled, e.g. after treatment with antifungals may result in better response.

Original languageEnglish
Pages (from-to)7271-5
Number of pages5
Issue number51
Publication statusPublished - 16 Dec 2015


  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Bacterial
  • Aspergillosis, Allergic Bronchopulmonary
  • C-Reactive Protein
  • Female
  • Humans
  • Immunoglobulin G
  • Male
  • Mannose-Binding Lectin
  • Middle Aged
  • Pneumococcal Vaccines
  • Prospective Studies
  • Young Adult
  • Journal Article
  • Observational Study


Dive into the research topics of 'Response to pneumococcal polysaccharide vaccination in patients with chronic and allergic aspergillosis'. Together they form a unique fingerprint.

Cite this